RSV Vaccine Shows 88% Efficacy in Older Adults Over Two Seasons
Pfizer's bivalent RSV vaccine demonstrated high efficacy and strong immune responses in adults 60+ across two respiratory virus seasons.
Summary
A phase 3 trial of Pfizer's bivalent RSV prefusion F vaccine in adults aged 60 and older showed impressive results over two respiratory syncytial virus seasons. The vaccine demonstrated 88.9% efficacy against RSV-associated lower respiratory tract illness in the first season and 77.8% in the second season. One month after vaccination, participants showed a 12-fold increase in neutralizing antibodies that remained elevated before the second season. The vaccine produced robust immune responses across all age groups (60-69, 70-79, and 80+ years) and in participants with chronic conditions. Safety profiles remained favorable throughout both seasons, supporting the vaccine's potential for protecting older adults from serious RSV infections.
Detailed Summary
Respiratory syncytial virus (RSV) poses a significant threat to older adults, causing serious lower respiratory tract infections. This comprehensive phase 3 trial evaluated Pfizer's bivalent RSV prefusion F vaccine over two complete RSV seasons in participants aged 60 and older.
The study randomized participants to receive either the 120-µg RSVpreF vaccine or placebo, tracking efficacy, safety, and immune responses. Researchers measured neutralizing antibody levels and monitored for RSV-associated lower respiratory tract illness with three or more symptoms.
Results showed remarkable vaccine efficacy of 88.9% in the first season and 77.8% in the second season against symptomatic RSV illness. Immunogenicity data revealed a 12.1-fold increase in neutralizing antibodies one month post-vaccination for combined RSV-A and RSV-B strains. While antibody levels decreased by the second season, they remained 4.7 times higher than baseline, indicating durable immune protection.
Importantly, the vaccine performed consistently across age subgroups, with similar robust responses in participants aged 60-69, 70-79, and 80+ years. Those with chronic medical conditions also showed comparable immune responses to healthy participants, suggesting broad applicability.
These findings represent a significant advancement in protecting older adults from RSV, which can cause severe complications including hospitalization and death in this vulnerable population. The sustained efficacy and safety profile over two seasons supports the vaccine's potential as an important public health intervention for aging populations worldwide.
Key Findings
- 88.9% vaccine efficacy against symptomatic RSV illness in first season, 77.8% in second season
- 12-fold increase in neutralizing antibodies one month after vaccination
- Durable immune response with 4.7-fold higher antibodies before second season
- Consistent efficacy across all age groups including those 80 years and older
- Similar immune responses in participants with and without chronic conditions
Methodology
This was a randomized, placebo-controlled phase 3 trial conducted over two RSV seasons in participants aged 60 and older. Participants received either 120-µg RSVpreF vaccine or placebo in a 1:1 ratio, with immunogenicity assessed in US and Japanese participants.
Study Limitations
Only abstract data is available, limiting detailed analysis of adverse events, specific participant characteristics, and statistical confidence intervals. Long-term durability beyond two seasons remains unknown, and real-world effectiveness may differ from controlled trial conditions.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.